- Home
- ENGS vs BCAB Comparison
ENGS vs BCAB Comparison
Compare ENGS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGS
- BCAB
- Stock Information
- Founded
- ENGS 1998
- BCAB 2007
- Country
- ENGS United Kingdom
- BCAB United States
- Employees
- ENGS N/A
- BCAB N/A
- Industry
- ENGS
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- ENGS
- BCAB Health Care
- Exchange
- ENGS NYSE
- BCAB Nasdaq
- Market Cap
- ENGS 23.8M
- BCAB 22.3M
- IPO Year
- ENGS 2025
- BCAB 2020
- Fundamental
- Price
- ENGS $1.78
- BCAB $0.40
- Analyst Decision
- ENGS
- BCAB Buy
- Analyst Count
- ENGS 0
- BCAB 2
- Target Price
- ENGS N/A
- BCAB $1.00
- AVG Volume (30 Days)
- ENGS 399.3K
- BCAB 523.2K
- Earning Date
- ENGS 01-01-0001
- BCAB 08-07-2025
- Dividend Yield
- ENGS N/A
- BCAB N/A
- EPS Growth
- ENGS N/A
- BCAB N/A
- EPS
- ENGS N/A
- BCAB N/A
- Revenue
- ENGS $11,089,930.00
- BCAB $11,000,000.00
- Revenue This Year
- ENGS N/A
- BCAB N/A
- Revenue Next Year
- ENGS N/A
- BCAB N/A
- P/E Ratio
- ENGS N/A
- BCAB N/A
- Revenue Growth
- ENGS 6.58
- BCAB N/A
- 52 Week Low
- ENGS $1.36
- BCAB $0.24
- 52 Week High
- ENGS $10.24
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- ENGS N/A
- BCAB 46.46
- Support Level
- ENGS N/A
- BCAB $0.36
- Resistance Level
- ENGS N/A
- BCAB $0.43
- Average True Range (ATR)
- ENGS 0.00
- BCAB 0.04
- MACD
- ENGS 0.00
- BCAB -0.00
- Stochastic Oscillator
- ENGS 0.00
- BCAB 30.65
About ENGS ENERGYS GROUP LTD
Energys Group Ltd provides end-to-end customized solutions and services involving the retrofitting of existing infrastructure to reduce their CO2 emissions. The Company's customers include large national account end-users, including universities, schools, hospitals and electrical distributors in the United Kingdom.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.